New drug duo shows promise against tough liver cancer
NCT ID NCT03463876
Summary
This study tested whether combining two different cancer drugs could help control advanced liver cancer in patients whose previous treatment stopped working. The trial involved 190 participants who received both an immunotherapy drug (SHR-1210) and a targeted therapy drug (apatinib). Researchers measured how well the combination shrank tumors and controlled the cancer, while closely monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Beijing, Beijing Municipality, 100071, China
Conditions
Explore the condition pages connected to this study.